KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Cash from Operations (2018 - 2025)

Historic Cash from Operations for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to $2.4 billion.

  • Takeda Pharmaceutical's Cash from Operations fell 393.41% to $2.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $8.9 billion, marking a year-over-year increase of 203.3%. This contributed to the annual value of $7.9 billion for FY2025, which is 2448.89% up from last year.
  • As of Q4 2025, Takeda Pharmaceutical's Cash from Operations stood at $2.4 billion, which was down 393.41% from $2.6 billion recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Cash from Operations registered a high of $5.7 billion during Q1 2021, and its lowest value of $651.4 million during Q2 2022.
  • Over the past 5 years, Takeda Pharmaceutical's median Cash from Operations value was $2.3 billion (recorded in 2021), while the average stood at $2.3 billion.
  • In the last 5 years, Takeda Pharmaceutical's Cash from Operations skyrocketed by 32488.51% in 2021 and then crashed by 6299.25% in 2023.
  • Takeda Pharmaceutical's Cash from Operations (Quarter) stood at $3.1 billion in 2021, then fell by 12.43% to $2.7 billion in 2022, then crashed by 62.99% to $990.8 million in 2023, then soared by 154.78% to $2.5 billion in 2024, then dropped by 3.93% to $2.4 billion in 2025.
  • Its last three reported values are $2.4 billion in Q4 2025, $2.6 billion for Q3 2025, and $1.5 billion during Q2 2025.